Global Blood Therapeutics, Inc.
GBT was delisted on the 4th of October, 2022.
96 hedge funds and large institutions have $367M invested in Global Blood Therapeutics, Inc. in 2016 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 42 increasing their positions, 18 reducing their positions, and 14 closing their positions.
133% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 18
86% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 14
14% more funds holding
Funds holding: 84 → 96 (+12)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
3% less call options, than puts
Call options by funds: $759K | Put options by funds: $785K
25% less capital invested
Capital invested by funds: $488M → $367M (-$121M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$17.6M |
| 2 |
PA
Perceptive Advisors
New York
|
+$14M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$12.7M |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$10.3M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$6.02M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$8.62M |
| 2 |
IHM
Iguana Healthcare Management
New York
|
-$8.35M |
| 3 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
-$6.89M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$4.61M |
| 5 |
Asset Management One
Tokyo,
Japan
|
-$2.67M |
GBT Hedge Fund Activity: Q4 2016 in Review
96 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Global Blood Therapeutics, Inc. (GBT) for Q4 2016, worth a combined $367M — down 25% from $488M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new GBT positions and 14 closed out — a net gain of 12 holders — while 42 added to existing stakes and 18 trimmed.
The largest buyer was Great Point Partners, opening a new position worth an estimated $17.6M. The largest seller was Driehaus Capital Management, exiting entirely with an estimated $8.62M sold.
- 96 institutional investors held Global Blood Therapeutics, Inc. (GBT) as of Q4 2016, up from 84 in Q3 2016.
- Funds reported $367M of Global Blood Therapeutics, Inc. stock for Q4 2016, down 25% quarter-over-quarter.
- 26 funds opened new Global Blood Therapeutics, Inc. positions in Q4 2016 and 14 closed out, a net change of +12 holders.
- The largest Global Blood Therapeutics, Inc. buyer in Q4 2016 was Great Point Partners, an estimated $17.6M added.
- The largest Global Blood Therapeutics, Inc. seller in Q4 2016 was Driehaus Capital Management, an estimated $8.62M sold.
Based on aggregated 13F filings for Q4 2016.